LMR Partners’s Viridian Therapeutics VRDN Stock Holding History

LMR Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.7K	Buy	+1,159	New	+$34.4K	﹤0.01%	1344
2024 Q1	–	Sell	-10,000	Closed	-$218K	–	1324
2023 Q4	$218K	Hold	10,000	–	–	﹤0.01%	726
2023 Q3	$153K	Hold	10,000	–	–	﹤0.01%	653
2023 Q2	$238K	Sell	10,000 -10,000	-50%	-$256K	﹤0.01%	572
2023 Q1	$509K	Sell	20,000 -30,000	-60%	-$962K	0.01%	730
2022 Q4	$1.46M	Buy	50,000 +9,213	+23%	+$212K	0.03%	620
2022 Q3	$837K	Sell	40,787 -39,610	-49%	-$712K	0.02%	780
2022 Q2	$930K	Buy	80,397 +27,623	+52%	+$371K	0.02%	789
2022 Q1	$976K	Buy	52,774 +11,374	+27%	+$219K	0.01%	839
2021 Q4	$818K	Buy	41,400 +7,892	+24%	+$147K	0.01%	788
2021 Q3	$551K	Buy	+33,508	New	+$491K	0.01%	763
2019 Q4	–	Sell	-989	Closed	-$11K	–	560
2019 Q3	$11K	Hold	989	–	–	﹤0.01%	411
2019 Q2	$30K	Buy	+989	New	+$39.7K	﹤0.01%	390

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LMR Partners's VRDN Position: Q1 2026 in Review

LMR Partners opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 1,159 shares worth $22.7K. The stake represents ﹤0.01% of the portfolio and ranks #1344 among its holdings. This is a return to the name: LMR Partners previously reported a position in VRDN as recently as Q4 2023.

LMR Partners first reported a position in VRDN in Q2 2019 and has held it in 13 quarters since. The position peaked at $1.46M in Q4 2022. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

LMR Partners held 1,159 shares of Viridian Therapeutics worth $22.7K as of Q1 2026.
Viridian Therapeutics was a new LMR Partners position in Q1 2026.
Viridian Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1344 holding.
LMR Partners first reported a position in Viridian Therapeutics in Q2 2019 and has held it in 13 quarters since.
LMR Partners's Viridian Therapeutics position peaked at $1.46M in Q4 2022.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.